

Ashley M Groves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10739541/publications.pdf>

Version: 2024-02-01

63
papers

2,763
citations

159358

30
h-index

182168

51
g-index

64
all docs

64
docs citations

64
times ranked

3965
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of ¹⁸ F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation. <i>Journal of Nuclear Medicine</i> , 2022, 63, 270-273.	2.8	9
2	Response to Bellaye et al. Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control. <i>European Respiratory Journal</i> , 2022, , 2103124.	3.1	0
3	Comparative accuracy and cost-effectiveness of dynamic contrast-enhanced CT and positron emission tomography in the characterisation of solitary pulmonary nodules. <i>Thorax</i> , 2022, 77, 988-996.	2.7	4
4	Filtration-histogram based texture analysis and CALIPER based pattern analysis as quantitative CT techniques in idiopathic pulmonary fibrosis: head-to-head comparison. <i>British Journal of Radiology</i> , 2022, 95, 20210957.	1.0	3
5	Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNik diagnostic accuracy study and economic modelling. <i>Health Technology Assessment</i> , 2022, 26, 1-180.	1.3	0
6	CT texture-based radiomics analysis of carotid arteries identifies vulnerable patients: a preliminary outcome study. <i>Neuroradiology</i> , 2021, 63, 1043-1052.	1.1	16
7	The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination. <i>Clinical Nuclear Medicine</i> , 2021, 46, 1006-1010.	0.7	29
8	FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 371-384.	3.3	10
9	Measurement of hypoxia in the lung in IPF: an F-MISO PET CT study. <i>European Respiratory Journal</i> , 2021, 58, 2004584.	3.1	6
10	Radiomics-Based Texture Analysis of ⁶⁸ Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With Neuroendocrine Cancers Treated With ¹⁷⁷ Lu-DOTATATE. <i>Frontiers in Oncology</i> , 2021, 11, 686235.	1.3	22
11	Validation of a combined image derived input function and venous sampling approach for the quantification of [¹⁸ F]GE-179 PET binding in the brain. <i>NeuroImage</i> , 2021, 237, 118194.	2.1	17
12	The role of PET in imaging of the tumour microenvironment and response to immunotherapy. <i>Clinical Radiology</i> , 2021, 76, 784.e1-784.e15.	0.5	4
13	Consensus Recommendations on the Use of ¹⁸ F-FDG PET/CT in Lung Disease. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1701-1707.	2.8	8
14	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1189-1201.	1.2	38
15	Synergistic application of pulmonary ¹⁸ F-FDG PET/HRCT and computer-based CT analysis with conventional severity measures to refine current risk stratification in idiopathic pulmonary fibrosis (IPF). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2023-2031.	3.3	19
16	Magnetic Resonance Texture Analysis in Identifying Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 163-170.	0.7	48
17	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 523-532.	5.2	50
18	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 529-537.	3.7	51

#	ARTICLE	IF	CITATIONS
19	A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 53, 1801992.	3.1	101
20	Mass Preservation for Respiratory Motion Registration in both PET and CT. , 2019, , .		1
21	Development of PET/CT and PET/MRI Patient-Information Videos in Collaboration with Patients Previously Treated for Cancer. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 26-28.	0.4	1
22	Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 806-815.	3.3	60
23	Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 757-767.	0.5	126
24	Additional Clinical Value for PET/MRI in Oncology: Moving Beyond Simple Diagnosis. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1028-1032.	2.8	20
25	Improved quantitation and reproducibility in multi-PET/CT lung studies by combining CT information. <i>EJNMMI Physics</i> , 2018, 5, 14.	1.3	3
26	Quantification of Lung PET Images: Challenges and Opportunities. <i>Journal of Nuclear Medicine</i> , 2017, 58, 201-207.	2.8	55
27	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Tj ETQq1 1 0.734314 rgBT /Ove		
28	Detection of Atherosclerotic Inflammation by 68 Ga-DOTATATE PET Compared to [18 F]FDG PET Imaging. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1774-1791.	1.2	321
29	The effect of respiratory induced density variations on non-TOF PET quantitation in the lung. <i>Physics in Medicine and Biology</i> , 2016, 61, 3148-3163.	1.6	25
30	Cerebral metabolism and perfusion in MR-negative individuals with refractory focal epilepsy assessed by simultaneous acquisition of 18 F-FDG PET and arterial spin labeling. <i>NeuroImage: Clinical</i> , 2016, 11, 648-657.	1.4	67
31	Improved correction for the tissue fraction effect in lung PET/CT imaging. <i>Physics in Medicine and Biology</i> , 2015, 60, 7387-7402.	1.6	48
32	Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1855-1861.	2.8	21
33	Predicting Aortic Aneurysm Expansion by PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 971-973.	2.8	4
34	Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 337-342.	3.3	65
35	CT signal heterogeneity of abdominal aortic aneurysm as a possible predictive biomarker for expansion. <i>Atherosclerosis</i> , 2014, 233, 510-517.	0.4	40
36	Correlation of Intra-Tumor 18F-FDG Uptake Heterogeneity Indices with Perfusion CT Derived Parameters in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e99567.	1.1	30

#	ARTICLE	IF	CITATIONS
37	Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non- ¹⁸ F Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3591-3599.	3.2	182
38	Novel Positron Emission Tomography/Computed Tomography of Diffuse Parenchymal Lung Disease Combining a Labeled Somatostatin Receptor Analogue and 2-Deoxy-2 [¹⁸ F] Fluoro-D-Glucose. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00030.	0.7	19
39	Defining the Role of PET-CT in Staging Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 613-619.	1.9	34
40	Integrated 18 F-Fluorodeoxyglucose-Positron Emission Tomography/Dynamic Contrast-Enhanced Computed Tomography to Phenotype Non-Small Cell Lung Carcinoma. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00052.	0.7	7
41	¹⁸ F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 521-528.	3.3	46
42	Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma. <i>Molecular Imaging</i> , 2012, 11, 353-60.	0.7	6
43	¹⁸ F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 46-52.	3.3	52
44	The importance of correction for tissue fraction effects in lung PET: preliminary findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 2238-2246.	3.3	58
45	A Comparison of ⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT in Pulmonary Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1927-1932.	2.8	228
46	Idiopathic Pulmonary Fibrosis and Diffuse Parenchymal Lung Disease: Implications from Initial Experience with ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 538-545.	2.8	138
47	Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 416-421.	3.3	43
48	First experience of combined cardiac PET/64-detector CT angiography with invasive angiographic validation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 2027-2033.	3.3	43
49	Advantages and Limitations of Imaging the Musculoskeletal System by Conventional Radiological, Radionuclide, and Hybrid Modalities. <i>Seminars in Nuclear Medicine</i> , 2009, 39, 357-368.	2.5	33
50	CT coronary angiography: Quantitative assessment of myocardial perfusion using test bolus data—initial experience. <i>European Radiology</i> , 2008, 18, 2155-2163.	2.3	20
51	How Do Patients Perceive the Benefits and Risks of Peripheral Angioplasty? Implications for Informed Consent. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 177-181.	0.2	17
52	Perfusion Scintigraphy Still has Important Role in Evaluation of Majority of Pregnant Patients with Suspicion of Pulmonary Embolism. <i>Radiology</i> , 2007, 244, 623-625.	3.6	8
53	Non-[¹⁸ F]FDG PET in clinical oncology. <i>Lancet Oncology</i> , The, 2007, 8, 822-830.	5.1	117
54	Cardiac ⁸² rubidium PET/CT: initial European experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1965-1972.	3.3	21

#	ARTICLE	IF	CITATIONS
55	The effect of lung resection on pulmonary function and exercise capacity in lung cancer patients. <i>Respiratory Care</i> , 2007, 52, 720-6.	0.8	60
56	¹⁸ F-fluorodeoxyglucose PET/CT in cancer imaging. <i>Clinical Medicine</i> , 2006, 6, 240-244.	0.8	23
57	CT Pulmonary Angiography versus Ventilation-Perfusion Scintigraphy in Pregnancy: Implications from a UK Survey of Doctors' Knowledge of Radiation Exposure. <i>Radiology</i> , 2006, 240, 765-770.	3.6	72
58	Ventilation-Perfusion Scintigraphy to Predict Postoperative Pulmonary Function in Lung Cancer Patients Undergoing Pneumonectomy. <i>American Journal of Roentgenology</i> , 2006, 187, 1260-1265.	1.0	55
59	An International Survey of Hospital Practice in the Imaging of Acute Scaphoid Trauma. <i>American Journal of Roentgenology</i> , 2006, 187, 1453-1456.	1.0	65
60	How often do patients undergo repeat PET or PET/CT examinations? Experience from a UK institution. <i>Nuclear Medicine Communications</i> , 2005, 26, 137-139.	0.5	3
61	Oral contrast medium in PET/CT: should you or shouldn't you?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1160-1166.	3.3	39
62	Positron Emission Tomography with FDG to Show Thymic Carcinoid. <i>American Journal of Roentgenology</i> , 2004, 182, 511-513.	1.0	23
63	Myocardial perfusion scintigraphy: patients' perception of benefit and risk. <i>Nuclear Medicine Communications</i> , 2004, 25, 1219-1222.	0.5	8